AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
11 Apr 2023 07:00 AM
RNS
Update to arrangements with Sobi and Sanofi
05 Apr 2023 07:00 AM
RNS
Lynparza + Imfinzi met endpoint in ovarian cancer
03 Apr 2023 03:00 PM
RNS
Total Voting Rights
03 Apr 2023 07:00 AM
RNS
Ultomiris recommended for NMOSD EU approval
30 Mar 2023 07:00 AM
RNS
AstraZeneca completes KYM agreement for CMG901
27 Mar 2023 11:00 AM
RNS
Director/PDMR Shareholding
22 Mar 2023 11:00 AM
RNS
Notice of AGM
09 Mar 2023 07:00 AM
RNS
Imfinzi improved EFS in resectable lung cancer
08 Mar 2023 11:01 AM
RNS
Director/PDMR Shareholding
08 Mar 2023 11:00 AM
RNS
Director/PDMR Shareholding
06 Mar 2023 07:00 AM
RNS
Enhertu DESTINY-PanTumor02 shows positive results
01 Mar 2023 03:00 PM
RNS
Total Voting Rights
01 Mar 2023 07:00 AM
RNS
AstraZeneca prices a $2.25bn bond offering
24 Feb 2023 06:15 PM
RNS
AstraZeneca prices a EUR1.5bn bond offering
24 Feb 2023 02:05 PM
RNS
AstraZeneca acquires CinCor for cardiorenal asset
24 Feb 2023 11:00 AM
RNS
Director/PDMR Shareholding
23 Feb 2023 07:00 AM
RNS
AstraZeneca enters agreement with KYM for CMG901
22 Feb 2023 07:10 AM
RNS
Filing of Form 20-F with SEC
21 Feb 2023 11:00 AM
RNS
Annual Financial Report
13 Feb 2023 02:01 PM
RNS
Director/PDMR Shareholding
13 Feb 2023 02:00 PM
RNS
Director/PDMR Shareholding
09 Feb 2023 07:00 AM
RNS
Final Results
01 Feb 2023 03:00 PM
RNS
Total Voting Rights
26 Jan 2023 06:15 PM
RNS
Update on Evusheld US EUA
16 Jan 2023 07:00 AM
RNS
Acquisition of Neogene Therapeutics completed
11 Jan 2023 01:00 PM
RNS
Airsupra (PT027) approved in US for asthma
09 Jan 2023 07:00 AM
RNS
AstraZeneca acquire CinCor for cardiorenal asset
03 Jan 2023 03:00 PM
RNS
Total Voting Rights
30 Dec 2022 11:00 AM
RNS
Director/PDMR Shareholding
28 Dec 2022 07:05 AM
RNS
Calquence Japan approval for treatment-naïve CLL
28 Dec 2022 07:00 AM
RNS
Imfinzi, Imjudo approved in Japan for 3 cancers
21 Dec 2022 07:05 AM
RNS
Lynparza approved in EU for prostate cancer
21 Dec 2022 07:00 AM
RNS
Imfinzi approved in EU for biliary tract cancer
19 Dec 2022 07:20 AM
RNS
Enhertu recommended for EU approval in HER2-low BC
19 Dec 2022 07:15 AM
RNS
Enhertu approved in EU for gastric cancer
19 Dec 2022 07:10 AM
RNS
Imfinzi + Imjudo recommended for approvals in EU
19 Dec 2022 07:05 AM
RNS
Update on Imfinzi PEARL trial
19 Dec 2022 07:00 AM
RNS
Forxiga CHMP opinion for symptomatic chronic HF
15 Dec 2022 07:00 AM
RNS
Update on US review of Lynparza PROpel sNDA
08 Dec 2022 01:30 PM
RNS
Capivasertib PFS in HR-positive breast cancer
01 Dec 2022 03:00 PM
RNS
Total Voting Rights
01 Dec 2022 03:00 PM
RNS
Block listing Interim Review
30 Nov 2022 07:05 AM
RNS
AstraZeneca announces sale of West Chester site
29 Nov 2022 07:00 AM
RNS
AstraZeneca to acquire Neogene Therapeutics
23 Nov 2022 03:30 PM
RNS
Director/PDMR Shareholding
14 Nov 2022 07:10 AM
RNS
Enhertu recommended for EU approval in gastric
14 Nov 2022 07:05 AM
RNS
Imfinzi recommended for approval in the EU for BTC
14 Nov 2022 07:00 AM
RNS
Lynparza combo recommended in the EU for mCRPC
11 Nov 2022 07:00 AM
RNS
Imfinzi + Imjudo approved in US for lung cancer
10 Nov 2022 07:00 AM
RNS
YTD and Q3 2022 Results
AstraZeneca PLC, known as AZN on the London Stock Exchange (LSE), is an Anglo-Swedish multinational pharmaceutical and biotechnology company. Founded on April 6, 1999, AstraZeneca was formed through the merger of the Swedish Astra AB and the British Zeneca Group. The company's roots trace back to 1913, when Astra AB was established by a group of doctors and apothecaries in Södertälje, Sweden. Throughout the twentieth century, AstraZeneca grew into one of the largest pharmaceutical companies in the world. It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014). Today, AstraZeneca operates in over 100 countries and employs around 83,000 people. As a member of the LSEG, AZN continues to shape the global healthcare landscape. The company is committed to defeating diseases that impact people's health.
UK 100